Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?

David Grimwade, Martin S. Tallman

Research output: Contribution to journal › Editorial › peer-review

15 Citations (Scopus)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{d2d4548d6b2e440bae57b55ac5e1d10d,

title = "Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?",

author = "David Grimwade and Tallman, {Martin S.}",

year = "2011",

month = jan,

doi = "10.1016/j.leukres.2010.06.018",

language = "English",

volume = "35",

pages = "3 -- 7",

journal = "Leukemia Research",

publisher = "Elsevier Limited",

number = "1",

}